Mouse anti Human CD65s antibody, clone VIM-2 selectively recognizes the sialylated form of human CD65, known as CD65s (VIM-2 antigen), a leucocyte carbohydrate antigen expressed by granulocytes, monocytes and leukaemic cells of myelomonocytic lineage.
CD65s is aberrantly expressed on some acute myeloid leukaemias (AML) and clone VIM-2 has been reliably used as a marker for distinguishing between mature and undifferentiated AML. During normal myelopoiesis, expression of CD65s follows the disappearance of the progenitor antigen CD34.
Cross-linking of the CD65s antigen using clone VIM-2, has been shown to induce phagocyte cytoplasmic calcium flux, oxidative burst and degranulation (Lund-Johansen et al. 1992).
Purified IgM prepared by ammonium sulphate precipitation.
Sodium Azide (NaN3)
Bovine Serum Albumin
THP1 (human acute monocytic leukaemia cells)
Approx. Protein Concentrations
IgM concentration 0.1mg/ml
Reagents In The Kit
Preparing The Antibody
Phosphate buffered saline
Spleen cells from immunised Balb/c mice were fused with cells of the mouse NS-1 myeloma cell line.
Store at +4oC or at -20oC if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. This product is photosensitive and should be protected from light. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
18 months from date of despatch.
For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
2. Lund-johansen, F. et al. (1992) Activation of human phagocytes through carbohydrate antigens (CD15, sialyl-CD15, CDw17, and CDw65).J Immunol. 148 (10): 3221-9.
3. Knapp, W. et al. (1994) Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis.Cytometry. 18 (4): 187-98.
4. Lund-johansen, F. et al. (1990) Flow cytometric assay for the measurement of human bone marrow phenotype, function and cell cycle.Cytometry. 11 (5): 610-6.
5. Bengtson, P. et al. (2002) Polymorphonuclear Leukocytes from Individuals Carrying the G329A Mutation in the a1,3-Fucosyltransferase VII Gene (FUT7) Roll on E- and P-Selectins J Immunol. 169: 3940-6.
6. Buffone, A. et al. (2013) Silencing a1,3-fucosyltransferases in human leukocytes reveals a role for FUT9 during E-selectin mediated cell adhesion.J Biol Chem. 288: 1620-33.
7. Nakayama, F. et al. (2001) CD15 expression in mature granulocytes is determined by alpha 1,3-fucosyltransferase IX, but in promyelocytes and monocytes by alpha 1,3-fucosyltransferase IV.J Biol Chem. 276: 16100-6.
8. Rao, R.M. et al. (2001) The S128R polymorphism of E-selectin mediates neuraminidase-resistant tethering of myeloid cells under shear flow.Eur J Immunol. 32: 251-60.
9. Paietta, E. et al. (2003) Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.Leukemia. 17: 1544-50.
10. Bengtson, P. et al. (2001) Identification of a missense mutation (G329A;Arg(110)--> GLN) in the human FUT7 gene.J Biol Chem. 276: 31575-82.
11. Oehler, L. et al. (1998) Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics.J Exp Med. 187: 1019-28.